Vault-13

SR One Capital Management, LP

Redwood City, CA · CIK 1910264 · 13F filing filed 2025-05-13

SEC-registered investment adviser since 2020 · limited partnership

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
Redwood City, CA (main office)United States United Statesabout 10
LondonUnited Kingdom United Kingdom5

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$389.3m reported value -5.1% vs Q4 2024
12positions
98.3%in top 10
1 new 1 added 0 reduced 0 sold out vs Q4 2024

Holdings, Q1 2025

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ARCELLX INC COMMON STOCK ACLX ACLX 2,346,630 $153.9m39.54% 39.54% UnchangedShares held: Q2 2024 2.3m, Q3 2024 2.3m, Q4 2024 2.3m, Q1 2025 2.3m
2 ARS PHARMACEUTICALS INC COM SPRY SPRY 4,012,903 $50.5m12.97% 12.97% UnchangedShares held: Q2 2024 4.0m, Q3 2024 4.0m, Q4 2024 4.0m, Q1 2025 4.0m
3 MINERALYS THERAPEUTICS INC COM MLYS MLYS 3,127,933 $49.7m12.76% 12.76% AddedShares held: Q2 2024 2.0m, Q3 2024 2.0m, Q4 2024 2.0m, Q1 2025 3.1m +1.1m +1,111,111 55.1%
4 ZENAS BIOPHARMA INC COM ZBIO ZBIO 4,911,539 $38.8m9.97% 9.97% UnchangedShares held: Q2 2024 0, Q3 2024 4.9m, Q4 2024 4.9m, Q1 2025 4.9m
5 CRISPR THERAPEUTICS AG NAMEN AKT CRSP CRSP 1,048,951 $35.7m9.17% 9.17% UnchangedShares held: Q2 2024 1.0m, Q3 2024 1.0m, Q4 2024 1.0m, Q1 2025 1.0m
6 DESIGN THERAPEUTICS INC COM DSGN DSGN 6,526,476 $25.2m6.47% 6.47% UnchangedShares held: Q2 2024 6.5m, Q3 2024 6.5m, Q4 2024 6.5m, Q1 2025 6.5m
7 ALUMIS INC COM ALMS ALMS 1,959,896 $12.0m3.09% 3.09% UnchangedShares held: Q2 2024 2.0m, Q3 2024 2.0m, Q4 2024 2.0m, Q1 2025 2.0m
8 OCULIS HOLDING AG ORDINARY SHARES OCS OCS 322,500 $6.1m1.58% 1.58% NewShares held: Q2 2024 0, Q3 2024 0, Q4 2024 0, Q1 2025 322.5k
9 NKARTA INC COM NKTX NKTX 3,333,333 $6.1m1.58% 1.58% UnchangedShares held: Q2 2024 3.3m, Q3 2024 3.3m, Q4 2024 3.3m, Q1 2025 3.3m
10 ORUKA THERAPEUTICS INC COM ORKA ORKA 430,330 $4.4m1.13% 1.13% UnchangedShares held: Q2 2024 0, Q3 2024 375.3k, Q4 2024 430.3k, Q1 2025 430.3k
11 KALA BIO INC COM NEW COM NEW 598,940 $3.4m0.88% 0.88% UnchangedShares held: Q2 2024 443.7k, Q3 2024 443.7k, Q4 2024 598.9k, Q1 2025 598.9k
12 ENGENE HOLDINGS INC COM COM 747,750 $3.3m0.86% 0.86% UnchangedShares held: Q2 2024 500.0k, Q3 2024 747.8k, Q4 2024 747.8k, Q1 2025 747.8k